Question

Neovascular age-related macular degeneration is the leading cause of legal blindness in the United States. Ranibizumab has been approved by the Food and Drug Administration for the treatment of this disease, but is very expensive. Bevacizumab is much less expensive, and investigators want to determine whether bevacizumab can achieve results that are not worse than ranibizumab. Patients are randomized to either ranibizumab or bevacizumab and are treated simultaneously. Which study design best describes this trial? (CATT 2011)

Answer 1

Answer:

i don't understand the question

Explanation:

i don't understand the question